Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

Kappos, Ludwig; L. Arnold, Douglas; Bar‐Or, Amit; John Camm, A.; Derfuß, Tobias; Sprenger, Till; Davies, Martin; Piotrowska, Alexandra; Ni, Pingping; Harada, Tomohiko

doi:10.1177/1352458517728343

Public

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

Published in Multiple Sclerosis Journal • Sep 15, 2017

Authors:

Ludwig Kappos

Douglas L. Arnold

Amit Bar‐Or

Abstract

BACKGROUND: Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis. OBJECTIVE: To assess safety and e...

Subject

Multiple sclerosis

Medicine

Extension (predicate logic)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!